Kazeka V. Optimization of antiretroviral treatment of HIV-infected people using injecting drugs, opioid agonists

Scientific work is devoted to increasing the effectiveness of antiretroviral therapy in HIV-infected people using injecting drugs, with the use of a combined treatment strategy with the use of substitution maintenance therapy with opioid agonists. The work is based on a prospective cohort study within 48 weeks assessing the effect of substitution maintenance therapy with opioid agonists in HIV-infected people who inject drugs on the effectiveness of antiretroviral therapy compared to HIV-infected people who inject drugs without substitution maintenance therapy and sexually transmitted infections. The degree of psychotic and depressive disorders on the scales BPRS and MADRS in patients with HIV infection, people who inject drugs in groups 1 and 2, before the start of treatment, did not differ statistically. It is shown that in the context of substitution maintenance therapy in HIV-infected people who inject drugs, the degree of psychotic and depressive disorders on the scale of BPRS and MADRS, and the proportion of patients with complete viral suppression in the HIV- Infected people who use injecting drugs in the context of substitution maintenance therapy after 48 weeks of antiretroviral therapy are greater than in the group of HIV-infected people who inject drugs without substitution maintenance therapy and do not differ from HIV infected groups sexually transmitted infections. In patients with HIV infection, people who use injecting drugs found a direct correlation between high power between BPRS (R=0,72) and MADRS (R=0,71) before the start of antiretroviral therapy and the level of viral load of HIV-RNA at the 24-th week of treatment. Thus, in people with HIV who use injecting drugs, when evaluating the BPRS scale more than 41 points and/or the MADRS score of more than 14 points, one can predict the virologic ineffectiveness of antiretroviral therapy at the 24-th week of treatment.